<DOC>
	<DOCNO>NCT01706926</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy 3 subcutaneous dos mavrilimumab compare placebo combination methotrexate ( MTX ) subject moderate-to-severe adult onset Rheumatoid Arthritis ( RA ) .</brief_summary>
	<brief_title>A Study Mavrilimumab Subjects With Moderate-to-Severe Rheumatoid Arthritis</brief_title>
	<detailed_description>Despite therapeutic improvement recent biologic agent approve rheumatoid arthritis , still significant unmet medical need treatment subject chronic disease achieve faster , complete response , high rate remission . The aim study explore optimum dose mavrilimumab clinical development fully investigate efficacy safety profile mavrilimumab longer drug exposure ( , 24 week ) . The result study form basis future clinical study mavrilimumab .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>A diagnosis adult onset Rheumatoid Arthritis ( RA ) line protocol Moderately active disease line protocol A predefined number swollen joint line protocol Inadequate response one conventional diseasemodifying antirheumatic drug ( DMARDs ) No evidence respiratory disease . A rheumatic autoimmune disease RA , significant systemic extraarticular involvement secondary RA A history , current , inflammatory joint disease RA Previous treatment investigational drug Discontinuation biologic DMARD due lack efficacy Noncompliant concurrent medication Noncompliance medical history criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Mavrilimumab</keyword>
	<keyword>CAM-3001</keyword>
</DOC>